How did MRSN's revenue and expenses trend in Q4 2024?

Mersana Therapeutics (MRSN) experienced a revenue of $16.36 million in Q4 2024, with notable expenses in research and development (R&D) and selling, general, and administrative (SG&A) costs:

1. **Revenue Stability**: The company's revenue remained at $16.36 million, indicating a stable financial performance during the quarter.
2. **Increased Costs**: The Cost of Goods Sold (COGS) was $22.29 million, which is significantly higher than the revenue. This suggests that MRSN faced challenges in managing its cost of goods sold compared to its revenue generation.
3. **R&D Investments**: MRSN continued to invest heavily in R&D, with expenses amounting to $8.89 million. This reflects the company's commitment to innovation and development, which is crucial for its long-term growth in the biotech sector.
4. **SG&A Expenses**: The Selling, General, and Administrative (SG&A) expenses were not provided separately from the COGS, which makes it difficult to assess the specific components of these expenses. However, the total expenses of $22.29 million (COGS + SG&A) indicate that MRSN had substantial overhead costs during the quarter.

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|Cost of Goods Sold|R&D Expenses|Total Revenue|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|---|---|---|
|MRSN|MRSN.O|Mersana Therapeutics|2024 Q1|1.156E7||1.8686E7|9245000||185|
|MRSN|MRSN.O|Mersana Therapeutics|2024 Q2|1.0503E7||1.7245E7|2293000||185|
|MRSN|MRSN.O|Mersana Therapeutics|2024 Q3|9864000||1.4803E7|1.2598E7||185|
|MRSN|MRSN.O|Mersana Therapeutics|2024 Q4|8886000||2.2286E7|1.6361E7||185|